Compare ATGL & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATGL | CVRX |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.1M | 237.1M |
| IPO Year | 2023 | 2021 |
| Metric | ATGL | CVRX |
|---|---|---|
| Price | $15.00 | $7.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.50 |
| AVG Volume (30 Days) | 817.0 | ★ 251.3K |
| Earning Date | 01-27-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $56,651,000.00 |
| Revenue This Year | N/A | $17.17 |
| Revenue Next Year | N/A | $17.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.45 |
| 52 Week Low | $9.01 | $4.37 |
| 52 Week High | $50.00 | $11.30 |
| Indicator | ATGL | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.97 | 46.18 |
| Support Level | $9.01 | $6.74 |
| Resistance Level | $20.25 | $8.09 |
| Average True Range (ATR) | 0.77 | 0.55 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 61.35 | 55.39 |
Alpha Technology Group Ltd operates through its subsidiaries, which are established cloud-based IT solution service providers in Hong Kong. Its Operating Subsidiaries utilize its analytic skills, programming skills, artificial intelligence technologies and technological know-how to provide comprehensive solutions designed to optimize the business performance of customers, meet various industry-specific operational challenges of customers and create new business opportunities for customers. The Operating Subsidiaries provide services for customers from a variety of industries, including consulting, real estate, architectural design, carpark management, electronic payment services, logistics, investments, retail, textiles, wholesale and distribution, etc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.